Replay has a portfolio of gene writing technologies that include an algorithm for rewriting proteins, a genome writing platform, immune silencing technology and technology that facilitates gene delivery.
“Our ability to write and deliver big DNA has the potential to disrupt many areas of genomic medicine. We have the right team, corporate structure, portfolio of technology platforms and financial backing to build an enduring company that shapes the future of the industry,” said Replay co-founder and CEO Lachlan MacKinnon in a July 25 press release.
This seed funding round was led by Kolhberg Kravis Roberts and OMX Ventures.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
